View Products

Search Products

Order Form

Rejuvenation Medicine

FAQs

Health Concerns

Contact Us

Who We Are

Home

CHATSWORTH, Calif.--(BUSINESS WIRE) via NewsEdge Corporation -- Natrol Inc. (Nasdaq:NTOL), a manufacturer and distributor of nationally branded dietary supplements and a leading distributor of ENADA(R) NADH (ENADA) manufactured by Menuco Corp., today commented on the release of an FDA-approved study on Chronic Fatigue Syndrome (CFS).

CFS is a debilitating disorder that causes unexplainable tiredness or lack of energy. It is estimated that CFS affects more than 14 million Americans.

According to a report published by Menuco, "results of an FDA-approved, double-blind, placebo-controlled cross-over study published in the February 1999 issue of Annals of Allergy, Asthma and Immunology, found that CFS patients taking ENADA, a dietary supplement, were four times more likely to show improvements compared to those taking a placebo.

"A follow-up open label study showed 72 percent of the patients taking ENADA achieved continued marked improvement over time. After more than 18 months of using ENADA more than 80 percent of the CFS patients continue to experience improvement in their condition."

Business Wire, 11-18-99, 16:09 Eastern

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.